{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:53:20Z","timestamp":1778284400010,"version":"3.51.4"},"reference-count":48,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The rare aggressive pituitary adenoma presents a special challenge, due to the heterogenous presentation of the disease. The prognosis of aggressive pituitary adenomas has been improved due to recent studies demonstrating clinically-relevant efficacy of temozolomide, which is now considered first-line chemotherapy. However, there is limited data on second-line therapies in patients with treatment failure. This review presents a summary on the potential of medical therapies in aggressive pituitary tumors.<\/jats:p>","DOI":"10.1055\/a-1331-6939","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T23:33:58Z","timestamp":1615332838000},"page":"186-193","source":"Crossref","is-referenced-by-count":4,"title":["Medical Therapy of Aggressive Pituitary Tumors"],"prefix":"10.1055","volume":"129","author":[{"given":"Stephan","family":"Petersenn","sequence":"additional","affiliation":[{"name":"ENDOC Center for Endocrine Tumors, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/eje.1.02326","article-title":"Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry","volume":"156","author":"W Saeger","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"G Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement","volume":"20","author":"F F Casanueva","year":"2017","journal-title":"Pituitary"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40478-015-0229-8","article-title":"Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications","volume":"3","author":"C P Miermeister","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1210\/jc.2009-0471","article-title":"Predicting recurrence of nonfunctioning pituitary adenomas","volume":"94","author":"T W Noh","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3171\/2008.4.17517","article-title":"Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression","volume":"111","author":"G Widhalm","year":"2009","journal-title":"J Neurosurg"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: A multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"J Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1530\/EJE-18-0749","article-title":"Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: Retrospective analysis on 566 patients from a tertiary care centre","volume":"180","author":"S Asioli","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cen.14197","article-title":"A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s","volume":"93","author":"F Guaraldi","year":"2020","journal-title":"Clinical Endocrinology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11154-020-09551-y","article-title":"Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives","volume":"21","author":"P Burman","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/nop\/npv059","article-title":"Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports","volume":"3","author":"Y Ji","year":"2016","journal-title":"Neuro-Oncology Practice"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: Results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"A McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-020-01040-4","article-title":"Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature","volume":"23","author":"L Lizzul","year":"2020","journal-title":"Pituitary"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11060-020-03579-5","article-title":"Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas","volume":"149","author":"G Minniti","year":"2020","journal-title":"J Neurooncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1210\/jc.2011-2031","article-title":"Clinical review: Pituitary carcinoma: Difficult diagnosis and treatment","volume":"96","author":"A P Heaney","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","first-page":"1","article-title":"Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. Case Reports in","volume":"2013","author":"R F Cornell","year":"2013","journal-title":"Endocrinology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11060-017-2554-1","article-title":"Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: A pediatric case report and review of the literature","volume":"135","author":"M S AbdelBaki","year":"2017","journal-title":"Journal of Neuro-Oncology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1210\/jcem.83.12.5300","article-title":"The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors","volume":"83","author":"G A Kaltsas","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ando.2018.07.013","article-title":"Pasireotide: A potential therapeutic alternative for resistant prolactinoma","volume":"80","author":"H Lasolle","year":"2019","journal-title":"Ann Endocrinol (Paris)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"K21","DOI":"10.1530\/EJE-19-0279","article-title":"Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma","volume":"181","author":"E C Coopmans","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/EJE-19-0359","article-title":"Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors","volume":"181","author":"G Raverot","year":"2019","journal-title":"European Journal of Endocrinology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11102-011-0346-8","article-title":"Anti-VEGF therapy in pituitary carcinoma","volume":"15","author":"L D Ortiz","year":"2012","journal-title":"Pituitary"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","article-title":"Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection","volume":"41","author":"W Touma","year":"2017","journal-title":"J Clin Neurosci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.wneu.2018.11.011","article-title":"Long-term survival after transformation of an adrenocorticotropic hormone-secreting pituitary macroadenoma to a silent corticotroph pituitary carcinoma","volume":"122","author":"L E Rotman","year":"2019","journal-title":"World Neurosurg"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1210\/jc.2019-00432","article-title":"Surgery, octreotide, temozolomide, bevacizumab, radiotherapy, and pegvisomant treatment of an aip mutation-positive child","volume":"104","author":"P Dutta","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.wneu.2018.12.174","article-title":"Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: Case report and literature review","volume":"124","author":"Y Wang","year":"2019","journal-title":"World Neurosurg"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11102-011-0341-0","article-title":"New targeted therapies in pituitary carcinoma resistant to temozolomide","volume":"15","author":"E Jouanneau","year":"2012","journal-title":"Pituitary"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/cns-2016-0011","article-title":"Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy","volume":"5","author":"L E Donovan","year":"2016","journal-title":"CNS Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas","volume":"104","author":"D Zhang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12020-013-0093-x","article-title":"Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors","volume":"46","author":"O Cooper","year":"2014","journal-title":"Endocrine"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/carcin\/22.8.1149","article-title":"Aberrant expression of G(1)\/S regulators is a frequent event in sporadic pituitary adenomas","volume":"22","author":"D J Simpson","year":"2001","journal-title":"Carcinogenesis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/2018.2.FOCUS17660","article-title":"Regression of a nonfunctioning pituitary macroadenoma on the CDK4\/6 inhibitor palbociclib: Case report","volume":"44","author":"E Anderson","year":"2018","journal-title":"Neurosurg Focus"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","article-title":"Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab","volume":"103","author":"A L Lin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-20-0151","article-title":"Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: A new emerging treatment","volume":"184","author":"B Sol","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: Two case reports and a review of the literature","volume":"10","author":"C Duhamel","year":"2020","journal-title":"J Pers Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","article-title":"Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab","volume":"31","author":"M Caccese","year":"2020","journal-title":"Anticancer Drugs"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1530\/EJE-10-0629","article-title":"Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: Experience in six cases","volume":"163","author":"M Losa","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1210\/jc.2010-0441","article-title":"Temozolomide treatment for aggressive pituitary tumors: Correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression","volume":"95","author":"Z M Bush","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1210\/jc.2010-0644","article-title":"Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: A french multicenter experience","volume":"95","author":"G Raverot","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1210\/jc.2012-2924","article-title":"DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors","volume":"98","author":"T Hirohata","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1210\/jc.2014-4350","article-title":"Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide","volume":"100","author":"D Bengtsson","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11060-014-1702-0","article-title":"Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center","volume":"122","author":"F Ceccato","year":"2015","journal-title":"J Neurooncol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/587893","article-title":"Temozolomide therapy for aggressive pituitary tumors: Results in a small series of patients from Argentina","volume":"2015","author":"O D Bruno","year":"2015","journal-title":"Int J of Endocrinol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","article-title":"Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas","volume":"126","author":"M Losa","year":"2016","journal-title":"Journal of Neuro-Oncology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas","volume":"176","author":"H Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"ref47","first-page":"64","article-title":"Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series","volume":"5","author":"J T Jordan","year":"2018","journal-title":"Neurooncol Pract"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1210\/clinem\/dgz211","article-title":"Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas-A German survey","volume":"105","author":"U Elbelt","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1055\/a-1060-1883","article-title":"Management of aggressive pituitary tumors \u2013 A 2019 update","volume":"51","author":"S Petersenn","year":"2019","journal-title":"Horm Metab Res"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1331-6939.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T23:55:00Z","timestamp":1617926100000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1331-6939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":48,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2021,3,9]]},"published-print":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1331-6939","relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}